SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

GameStop Corp. engages in offering games and entertainment products through its ecommerce properties and stores. The firm’s stores and ecommerce sites operate primarily under the names GameStop, EB Games, and Micromania. It operates through the following geographical segments: United States, Canada, Australia, and Europe. The company was founded by Daniel A. DeMatteo in 1996 and is headquartered in Grapevine, TX.

Gamestop Corporation - Ordinary Shares - Class A

GameStop Corp

GameStop is trending following reports that the company is preparing a formal bid for eBay, a move aimed at transforming the retailer into a massive e-commerce player. The community is actively debating the logistics of how GameStop, with its current cash reserves, would finance an acquisition of a company significantly larger than itself, while bulls anticipate a potential short squeeze and accelerated growth.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is experiencing a sharp rally driven by heavy short interest and speculative momentum as traders position themselves ahead of the company's upcoming earnings report. The community is actively discussing the potential for a short squeeze, citing high borrow fees and limited share availability while debating the long-term strategic value of the stock's recent partnership and acquisition activity.

eBay, Inc. is a commerce company, whose platforms include an online marketplace and its localized counterparts, including off-platform businesses in South Korea, Japan, and Turkey, as well as eBay’s suite of mobile apps. It offers a platform for various product categories, including parts and accessories, collectibles, fashion, electronics, and home & garden. eBay generates revenue mainly through fees from sales, payment processing, and advertising. The company was founded by Pierre Morad Omidyar in September 1995 and is headquartered in San Jose, CA.

EBay Inc.

eBay Inc

eBay is trending as market participants debate the impact of the end of the de minimis tariff exemption on its cross-border revenue and overall profit margins. While some traders are analyzing potential downside risks and short-term volatility, others remain focused on the company's long-term reliance on AI-driven marketplace improvements and the collectibles market to sustain growth.

Lionsgate Studios Corp. operates as a standalone, pure-play content company focused on creating, producing, and distributing premium entertainment across multiple formats and platforms. It operates through the following segments: Motion Picture and Television Production. The Motion Picture segment includes the development and production of feature films, acquisition of North American and worldwide distribution rights, North American theatrical, home entertainment, and television distribution of produced and acquired films, as well as the worldwide licensing of distribution rights. The Television Production segment covers the development, production, and worldwide distribution of television content, including series, television movies, mini-series, and non-fiction programming. The company was founded on January 13, 2025 and is headquartered in Vancouver, Canada.

Lionsgate Studios Corp. - Ordinary Shares - New

Lionsgate Studios Corp.

Lionsgate Studios is currently trending as a high-conviction buyout candidate, with investors actively discussing potential interest from major players like Netflix, Amazon, or Sony following the company's recent strategic spin-off. The community is heavily focused on the studio's strong IP library and the blockbuster box office potential of the Michael Jackson biopic as key catalysts that could drive a premium acquisition.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

The MullenArmy is actively rallying behind its SOL-based token, with community members coordinating to drive momentum and recreate the market cap surges seen in previous cycles. Discussions are heavily focused on potential price runs, community-led buy pressure, and calls for long-term holding to reach previous market cap milestones.

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community doubles down on long-term conviction, fueled by developer updates regarding a pivot toward business-oriented AI utility and a continued push for organic growth. Supporters are actively rallying behind the project's longevity and educational initiatives, viewing recent price action as a prime opportunity for accumulation before potential future developments.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, NEREUS, Ponvory, and HETLIOZAccess. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending as investors digest the commercial launch of NEREUS for motion sickness while debating the company's prospects for a potential buyout by major pharmaceutical players like Eli Lilly or Novo Nordisk. The community remains focused on the firm's strategic focus on GLP-1 adjunct treatments and active pipeline developments, even as participants express frustration over persistent price volatility and the company's aggressive regulatory strategy.

Pershing Square, Inc. operates as an alternative asset management company. It operates through the following business segments: Operating Assets, MPC,and Strategic Developments. The Operating Assets segment consists of developed or acquired retail, office, and multifamily properties along with other real estate investments. The MPC segments offers the development and sale of land in large-scale, long-term community development projects. The Strategic Developments segment provides residential condominium and commercial property projects currently under development. The company was founded by William A. Ackman on December 17, 2003 and is headquartered in New York, NY.

Pershing Square Inc.

Pershing Square Inc

Pershing Square is attracting intense market interest following its successful IPO, with investors closely watching Bill Ackman's strategy to navigate management fees and future fund launches. The community is actively debating the valuation and relationship between the management firm and its related closed-end fund, while monitoring for potential volatility as the IPO buzz settles.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics is trending following the announcement of a pivotal Phase 3 registration path for CAD-1005 in Heparin-Induced Thrombocytopenia, which followed a successful end-of-Phase 2 meeting with the FDA. While some investors are optimistic about the company's clinical progress and pipeline potential, a significant portion of the community is expressing frustration over frequent spam, bot activity, and concerns regarding the company's long-term financial stability and funding requirements.

$ORDI : first token deployed on Bitcoin Ordinals, with a 21 million supply. $DOGI : first token deployed on Dogecoin Ordinals, with a 21 million supply. The First DRC-20 token in the history

dogi

The DRC-20 token DOGI is gaining traction as investors highlight its integration with Doginals and the Doggy Market ecosystem alongside anticipation for upcoming utility developments. Community discussions are heavily focused on its role as a Dogecoin-based alternative to BRC-20 assets, with sentiment split between high-conviction accumulation and caution regarding broader meme coin volatility.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Emergent Biosolutions (NYSE:EBS) Posts Quarterly Earnings Results, Beats Expectations By $0.46 EPS

Emergent Biosolutions (NYSE:EBS - Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported $0.21 earnings per share (EPS) for the quarter, beating...

Emergent BioSolutions Q1 2026 Earnings Call: Complete Transcript

Q1 Earnings Estimate for EBS Issued By Benchmark

Emergent Biosolutions Inc. (NYSE:EBS - Free Report) - Stock analysts at Benchmark issued their Q1 2026 earnings per share estimates for Emergent Biosolutions in a research report issued on Tuesday...

Emergent Biosolutions (EBS) Expected to Announce Quarterly Earnings on Thursday

Emergent Biosolutions (NYSE:EBS) will be releasing its Q1 2026 earnings after the market closes on Thursday, April 30. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2026-4-30-emergent-biosolutions-inc-stock...

HC Wainwright Lowers Emergent Biosolutions (NYSE:EBS) Price Target to $12.00

HC Wainwright decreased their target price on shares of Emergent Biosolutions from $15.00 to $12.00 and set a "buy" rating for the company in a research note on Monday...

Emergent Biosolutions (NYSE:EBS) Cut to Hold at Wall Street Zen

Wall Street Zen downgraded shares of Emergent Biosolutions from a "buy" rating to a "hold" rating in a report on Sunday...

Wall Street Zen Downgrades Emergent Biosolutions (NYSE:EBS) to Buy

Wall Street Zen cut shares of Emergent Biosolutions from a "strong-buy" rating to a "buy" rating in a research report on Saturday...

Emergent Biosolutions Q4 Earnings Call Highlights

Emergent Biosolutions (NYSE:EBS) reported fourth-quarter and full-year 2025 results on a Feb. 26, 2026 earnings call, with management highlighting progress on its multi-year transformation plan...

<ul class="summary-bullets"><li>The company issues FY26 revenue guidance of $720 million-$760 million and Q1 guidance of $135 million-$155 million, both below consensus estimates.</li><li>Naloxone nasal spray revenues fell 41% due to rising competition, while anthrax biodefense product revenues rose 64% on delivery timing.</li><li>The company also announced new Canadian contracts worth up to C$140 million.</li></ul>Shares of Emergent BioSolutions, Inc. (EBS) fell over 20% in extended trading on Thursday after the company issued weaker-than-expected financial guidance for both the first quarter and full year 2026, overshadowing contract wins and a new stock buyback program.<a href="https://stocktwits.com/symbol/EBS">EBS stock</a> rose 0.8% in Thursday’s regular session.<h2 class="st-heading-2">Weak Outlook Weighs On Sentiment</h2>The biodefense company forecast full-year 2026 revenue in the range of $720 million to $760 million, below analysts’ consensus estimate of $809.4 million. The company also guided for first-quarter revenue of $135 million to $155 million, significantly below consensus expectations of $275 million.It also projected adjusted net income between $25 million and $45 million, and adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $135 million to $155 million."Our team remains focused on long-term sustainable value and achieving our vision of enabling several durable and profitable verticals in the Company over time," said CEO Joe Papa.<h2 class="st-heading-2">Earnings Miss Adds Pressure</h2>The cautious outlook came alongside weaker quarterly performance. Emergent reported a fourth-quarter (Q4) loss of $0.43 per share, compared with earnings of $0.05 per share a year earlier. Revenue came in at $148.7 million, missing expectations of $217.5 million.Naloxone product revenues from its opioid overdose reversal nasal sprays declined 41% due to increased competition. Anthrax medical countermeasure revenues, which include vaccines and treatments used for biodefense preparedness, rose 64%, driven by the timing of delivery. "Emergent's 2025 results demonstrate significant progress executing our multi-year turnaround strategy, delivering improved operating margins, strong adjusted EBITDA of $205 million, increased cash flow and lower leverage," Papa said.<h2 class="st-heading-2">Positive Developments Fail To Offset Concerns</h2>The company also announced new agreements worth up to C$140 million with the Canadian government agencies to supply medical countermeasures for biological threat preparedness. Emergent expects to receive more than C$35 million in orders from these contracts this year.Separately, the board authorized a new $50 million share repurchase program running through March 2027.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment for EBS was ‘extremely bullish’ amid a 285% surge in 24-hour message volume.<figure class="image"><img src="https://news.stocktwits-cdn.com/ebs_ss_png_5927fdd04b.webp" alt="ebs ss.png" width="976" height="140"><figcaption>EBS sentiment and message volume as of February 27 | Source: Stocktwits</figcaption></figure>One user&nbsp;<a href="https://stocktwits.com/ComradeKomisar/message/646069727">said</a>, “Pretty sure they 'sand bagged' the guidance, like they always do, and that order either will repeat, or we'll get it from Canada which can be threatned to lose the Winnipeg site, and move it to the US.”<stembedurl>https://stocktwits.com/ComradeKomisar/message/646069727</stembedurl>Another user&nbsp;<a href="https://stocktwits.com/Kawasaki1/message/646066600">said</a>, “Up 50 cents/ since the over reaction earlier...We were undervalued going into earnings and the future is still promising”<stembedurl>https://stocktwits.com/Kawasaki1/message/646066600</stembedurl>EBS stock has declined 10% year-to-date.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration the Emergent BioSolutions logo of an US biopharmaceutical company is seen on a smartphone and a pc screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

Why Did Emergent Biosolutions Stock Tumble 20% After-Hours Today?

The board authorized a new $50 million share repurchase program running through March 2027.

Equity

Emergent Biosolutions (NYSE:EBS) Releases Quarterly Earnings Results

Emergent Biosolutions (NYSE:EBS - Get Free Report) released its earnings results on Thursday. The biopharmaceutical company reported ($0.43) earnings per share (EPS) for the quarter, missing...

$EBS Q1 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of $0.13 down -89.60% YoY
• Reported revenue of $156.1M down -29.75% YoY
• Emergent BioSolutions Inc. forecasts full-year 2026 total revenues of $720-$760 million, unchanged, and revised adjusted net income to $45-$65 million and adjusted EBITDA to $155-$175 million.

Stocktwits

Emergent Biosolutions Inc

 Q1 '26 Earnings Results & Recap

• Reported GAAP EPS of $0.13 down -89.60% YoY
• Reported revenue of $156.1M down -29.75% YoY
• Emergent BioSolutions Inc. forecasts full-year 2026 total revenues of $720-$760 million, unchanged, and revised adjusted net income to $45-$65 million and adjusted EBITDA to $155-$175 million.

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

Emergent BioSolutions Inc. engages in the development, manufacture, and commercialization of medical countermeasures. It operates through the following segments: Commercial Product Sales, MCM Product Sales, and Services. The Commercial Product Sales segment includes NARCAN products and other commercial products that were sold as part of the travel health business. The MCM Product Sales segment focuses on the Anthrax - MCM products, Smallpox - MCM products and other products. The Services segment consists of the company’s Bioservices offerings. It offers products for civilian and military populations that address accidental, intentional, and naturally occurring public health threats. The company was founded by Fuad El-Hibri on September 5, 1998 and is headquartered in Gaithersburg, MD.

EBS
Emergent Biosolutions Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EBS News

EBSEmergent Biosolutions Inc